World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
21609
World Ranking
18066
National Ranking
601

Overview

David Malka is affiliated with the Institut Mutualiste Montsouris in France and has contributed extensively to medical research, particularly in the fields of oncology and surgery. Their research portfolio includes a total of 252 publications focused primarily in medicine, with a strong emphasis on oncology (92 publications), surgery (61), pulmonary and respiratory medicine (45), cancer research (21), and pathology and forensic medicine (15).

Their main areas of study cover a spectrum of cancer-related topics, including cholangiocarcinoma and gallbladder cancer studies, pancreatic and hepatic oncology research, and colorectal cancer treatments and studies. Detailed topics researched include cancer genomics and diagnostics, gallbladder and bile duct disorders, genetic factors in colorectal cancer, and hepatocellular carcinoma treatment and prognosis.

David Malka's frequent co-authors include Antoine Hollebecque with 43 collaborations, Michel Ducreux (40), Valérie Boige (31), Cristina Smolenschi (30), and Julien Edeline (24). Their research results are regularly published in specialized medical journals with the most frequent venues being Annals of Oncology (22 publications), European Journal of Cancer (14), Journal of Clinical Oncology (11), Cancers (6), and Digestive and Liver Disease (4).

Notable recent papers authored by Malka or in collaboration include:

  • Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies, 2020, International Journal of Cancer
  • Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer, 2022, JAMA Oncology
  • Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer, 2020, Nature Medicine
  • Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial, 2022, Nature Medicine

Best Publications

  • FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

    Thierry Conroy;Pascal Hammel;Mohamed Hebbar;Meher Ben Abdelghani

  • Cutaneous side-effects of kinase inhibitors and blocking antibodies

    Caroline Robert;Jean-Charles Soria;Alain Spatz;Axel Le Cesne

  • Risk of pancreatic adenocarcinoma in chronic pancreatitis

    D Malka;P Hammel;F Maire;P Rufat

  • Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

    Julien Edeline;Meher Benabdelghani;Aurélie Bertaut;Jérôme Watelet

  • Risk factors for diabetes mellitus in chronic pancreatitis

    David Malka;Pascal Hammel;Alain Sauvanet;Pierre Rufat

  • Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

    David Malka;Pascale Cervera;Stéphanie Foulon;Tanja Trarbach

  • Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies

    Sarina A. Piha-Paul;Do Youn Oh;Makoto Ueno;David Malka

  • Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

    Thierry de Baère;Jean Palussière;Anne Aupérin;Antoine Hakime

  • Are G3 ENETS neuroendocrine neoplasms heterogeneous

    Fritz-Line Vélayoudom-Céphise;Pierre Duvillard;Lydia Foucan;Julien Hadoux

  • Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect

    Dominique Elias;Gabriel Liberale;Déwi Vernerey;Marc Pocard

  • Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy

    Diane Goéré;David Malka;Dimitri Tzanis;Vinicius Gava

  • Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis.

    D Elias;C Honoré;F Dumont;M. Ducreux

  • Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer.

    Maximilien Barret;Sami Antoun;Cécile Dalban;David Malka

  • Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT

    Clarisse Dromain;Sophie Leboulleux;Anne Auperin;Diane Goere

  • Advanced Hepatocellular Carcinoma: Early Evaluation of Response to Bevacizumab Therapy at Dynamic Contrast-enhanced US with Quantification—Preliminary Results

    Nathalie Lassau;Serge Koscielny;Linda Chami;Mohamed Chebil

  • Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure

    Valérie Boige;David Malka;Dominique Elias;Marine Castaing

  • Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05

    Valérie Boige;Jean Mendiboure;Jean-Pierre Pignon;Marie-Anne Loriot

  • Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.

    Boris Guiu;Boris Guiu;Frédéric Deschamps;Serge Aho;Flore Munck

  • Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.

    Dominique Elias;Diane Goéré;Daniela Di Pietrantonio;Valérie Boige

  • Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

    Jean Philippe Arnault;Janine Wechsler;Bernard Escudier;Alain Spatz

Frequent Co-Authors

Michel Ducreux
Michel Ducreux Institut Gustave Roussy
Valérie Boige
Valérie Boige Institut Gustave Roussy
Dominique Elias
Dominique Elias Institut Gustave Roussy
Julien Taieb
Julien Taieb Université Paris Cité
Thierry de Baere
Thierry de Baere Institut Gustave Roussy
Sophie Leboulleux
Sophie Leboulleux University of Geneva
Pascal Hammel
Pascal Hammel University of Paris-Saclay
Eric Baudin
Eric Baudin Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
Olivier Bouché
Olivier Bouché CHU de Reims

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in alternative pathways to a career in medicine or nursing? Online healthcare degrees now offer greater flexibility and speed than ever before. Many aspiring nurses are choosing online rn to bsn programs no clinicals, which allow registered nurses to advance their education without the need for additional in-person clinical hours.

For those looking to take their nursing credentials further, options like the fastest dnp online program help professionals earn a Doctor of Nursing Practice in a condensed timeframe. Some programs go even further by offering a dnp program without clinical hours, designed for experienced nurses seeking maximum convenience.

If you’re eager to enter the workforce quickly, you can explore what is the fastest way to become an lpn. Fast-track Licensed Practical Nurse (LPN) programs can put you on the path to a rewarding healthcare career in less time.

These online programs offer practical solutions but it’s important to research accreditation, state requirements, and career goals before enrolling.

Best Scientists Citing David Malka

Trending Scientists

Recently Published Articles